XML 72 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6
SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Significant Accounting Policies [Line Items]      
Number of Subsidiaries 2    
Pfizer Agreement, upfront payment received $ 60,000    
Common stock, par value per share $ 0.001 $ 0.001  
Options to purchase common stock not included in diluted LPS because the effect would be anti-dilutive 7,761,168 7,469,088 7,280,469
Protalix Bio Therapeutics Incorporation [Member]
      
Significant Accounting Policies [Line Items]      
Pfizer Agreement, future revenues and expense sharing percentage 40.00%    
Pfizer Incorporation [Member]
      
Significant Accounting Policies [Line Items]      
Pfizer Agreement, future revenues and expense sharing percentage 60.00%    
Upon Filing of Pediatric Investigation Plan to EMA [Member]
      
Significant Accounting Policies [Line Items]      
Pfizer Agreement, upfront payment received 5,000    
Upon each FDA and European Medicine Agency approval [Member]
      
Significant Accounting Policies [Line Items]      
Milestone payment triggered 25,000    
Upon FDAApproval [Member]
      
Significant Accounting Policies [Line Items]      
Milestone payment triggered 25,000    
Upon Near Term Clinical Development Milestones [Member]
      
Significant Accounting Policies [Line Items]      
Milestone payment triggered $ 8,300